Back to School: How biopharma can reboot drug development. Access exclusive analysis here
ABT lowered its EPS guidance for the second quarter to $0.51 from $0.53 and full year
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury